Compare EXPD & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EXPD | UTHR |
|---|---|---|
| Founded | 1979 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.0B | 22.5B |
| IPO Year | 1995 | 1999 |
| Metric | EXPD | UTHR |
|---|---|---|
| Price | $171.34 | $527.94 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 11 | 14 |
| Target Price | $133.00 | ★ $567.57 |
| AVG Volume (30 Days) | ★ 1.2M | 364.7K |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.03% | N/A |
| EPS Growth | 4.02 | ★ 13.07 |
| EPS | 1.71 | ★ 5.82 |
| Revenue | ★ $6,920,948,000.00 | $1,483,300,000.00 |
| Revenue This Year | $2.71 | $6.39 |
| Revenue Next Year | $3.74 | $14.18 |
| P/E Ratio | $102.51 | ★ $90.80 |
| Revenue Growth | ★ 13.49 | 2.38 |
| 52 Week Low | $110.48 | $272.18 |
| 52 Week High | $183.52 | $609.35 |
| Indicator | EXPD | UTHR |
|---|---|---|
| Relative Strength Index (RSI) | 50.16 | 43.36 |
| Support Level | $157.54 | $518.82 |
| Resistance Level | $183.52 | $542.66 |
| Average True Range (ATR) | 3.65 | 12.71 |
| MACD | -0.61 | -0.67 |
| Stochastic Oscillator | 39.09 | 24.82 |
Based in the US, Expeditors International of Washington is a non-asset-based third-party logistics provider, mainly focused on international freight forwarding. Its offers freight consolidation and forwarding, customs brokerage, warehousing and distribution, purchase order management, vendor consolidation, and numerous other value-added logistics services. It employs sophisticated IT systems and contracts with airlines and ocean carriers to move customers' freight across the globe. The firm operates more than 200 full-service office locations worldwide, in addition to numerous satellite locations. In 2025, Expeditors derived 36% of consolidated gross revenue from airfreight, 25% from ocean freight, and 39% from customs brokerage and other services.
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.